Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Harrow Health ( (HROW) ) has provided an announcement.
On March 24, 2026, Harrow, Inc. entered into a purchase agreement with BTIG, LLC and other initial purchasers to offer an additional $50 million of 8.625% Senior Notes due 2030, expanding an existing $250 million note series first issued in September 2025. The company and its guarantor subsidiaries then executed a First Supplemental Indenture with U.S. Bank Trust Company on March 27, 2026, under which the new notes form a single series with identical terms to the existing notes, aside from issuance date and price.
Harrow completed the private offering of the new notes on March 27, 2026, placing them with qualified institutional buyers in the U.S. under Rule 144A and certain offshore investors under Regulation S, and received approximately $48.7 million in net proceeds. The company plans to use the funds for general corporate purposes, including growth initiatives, product launches, upcoming product development, and potential strategic business development opportunities, bolstering its financial flexibility for future expansion.
The most recent analyst rating on (HROW) stock is a Sell with a $33.00 price target. To see the full list of analyst forecasts on Harrow Health stock, see the HROW Stock Forecast page.
Spark’s Take on HROW Stock
According to Spark, TipRanks’ AI Analyst, HROW is a Neutral.
The score is held back primarily by leveraged financials and historically weak/volatile cash flow conversion, alongside bearish technicals and a loss-making (negative P/E) valuation profile. These are partially offset by a positive earnings-call outlook with strong 2026 revenue/EBITDA guidance, though near-term headwinds and higher planned spending remain key risks.
To see Spark’s full report on HROW stock, click here.
More about Harrow Health
Harrow, Inc. is a specialty pharmaceutical company focused on ophthalmic products and related therapies for eye care providers and their patients. The company develops, markets, and distributes branded and compounded ophthalmic pharmaceuticals, targeting both the U.S. eye-care market and select international markets through strategic partnerships and distribution agreements.
Average Trading Volume: 742,909
Technical Sentiment Signal: Hold
Current Market Cap: $1.32B
For an in-depth examination of HROW stock, go to TipRanks’ Overview page.